Aytu Biopharma (AYTU) Net Shares Issued and Repurchased (2015 - 2025)
Aytu Biopharma's (AYTU) quarterly Net Shares Issued and Repurchased came in at $4818.0 in Q3 2025, down 5.53% year-over-year from $5100.0 in Q3 2024, and down 94.49% quarter-over-quarter from $87500.0 in Q2 2025.
Powered by 
Analysis
Aytu Biopharma (AYTU) Net Shares Issued and Repurchased (2015 - 2025) Analysis & Trends
Aytu Biopharma (AYTU) has reported Net Shares Issued and Repurchased for 10 consecutive years, with $4818.0 the latest figure, recorded in Q3 2025.
- On a quarterly basis, Net Shares Issued and Repurchased fell 5.53% year-over-year to $4818.0 in Q3 2025; TTM through Sep 2025 was $4818.0, a 5.53% decrease from a year earlier, with the FY2025 full-year figure at $87500.0, down 22.91% from the prior year.
- Net Shares Issued and Repurchased was $4818.0 for Q3 2025 at Aytu Biopharma, down from $87500.0 in the prior quarter.
- Over five years, Net Shares Issued and Repurchased peaked at $113500.0 in Q2 2024 and troughed at $74.0 in Q3 2022.
- A 5-year average of $53707.0 and a median of $59466.5 in 2021 frame the typical range for Net Shares Issued and Repurchased.
- Across the five-year window, Net Shares Issued and Repurchased tumbled 99.03% in 2022 and soared 151251.35% in 2023, its largest moves.
- Over 5 years, Net Shares Issued and Repurchased stood at $7645.0 in 2021, then plunged by 99.03% to $74.0 in 2022, then soared by 151251.35% to $112000.0 in 2023, then plunged by 95.45% to $5100.0 in 2024, then retreated by 5.53% to $4818.0 in 2025.
- The last three Net Shares Issued and Repurchased figures came in at $4818.0 (Q3 2025), $87500.0 (Q2 2025), and $87500.0 (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | - |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -3.07 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | - |
| 10 | Aytu Biopharma | 22.49 Mn | -4.22 Mn | 7.60 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 4,818.00 |
| Jun 30, 2025 | 87,500.00 |
| Mar 31, 2025 | 87,500.00 |
| Sep 30, 2024 | 5,100.00 |
| Jun 30, 2024 | 113,500.00 |
| Sep 30, 2023 | 112,000.00 |
| Jun 30, 2023 | 49,212.00 |
| Sep 30, 2022 | 74.00 |
| Sep 30, 2021 | 7,645.00 |
| Jun 30, 2021 | 69,721.00 |
| Jun 30, 2020 | 76,950.00 |
| Sep 30, 2019 | 5,150.00 |
| Jun 30, 2019 | 463,008.00 |
| Sep 30, 2018 | 11.00 |
| Jun 30, 2017 | 1,197.00 |
| Sep 30, 2015 | 50,000.00 |
| Jun 30, 2015 | 625,266.00 |